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Summary
 
Increased prevalence of C4 null alleles is a common feature of autoimmune
diseases. We have shown previously that complement-dependent prevention
of immune precipitation (PIP) is defective in patients with systemic lupus
erythematosus (SLE), and correlated this defect with C4A*Q0 and low levels
of the C4A isotype. To further clarify the role of C4A in the aetiology of SLE,
we now extend our studies to other diseases which have been associated with
C4A*Q0. The frequency of C4A*Q0 was increased in Icelandic patients with
coeliac disease (0·50; 
 
P
 
 <
 
 0·001), Grave’s disease (0·30; 
 
P
 
 =
 
 0·002) and insulin-
dependent diabetes mellitus (0·23; 
 
P
 
 =
 
 0·04) and in British patients with der-
matitis herpetiformis (0·42; 
 
P
 
 =
 
 0·002) and this was reflected in low levels of
C4A. In spite of this, PIP was normal in these patients, and in marked contrast
to our previous observations on connective tissue diseases, PIP measurements
in these patient groups correlated more strongly with levels of C4B (
 
r
 
 =
 
 0·51,
 
P
 
 =
 
 0·0000004) than C4A. Patients with increased levels of anti-C1q antibod-
ies had significantly lower PIP than patients without such antibodies
(
 
P <
 
 0·01) and a negative association of PIP with anti-C1q antibodies was also
reflected in an increased prevalence (
 
P
 
 =
 
 0·006) and levels (
 
P
 
 =
 
 0·006) of anti-
C1q antibodies in patients with subnormal PIP, as well as a negative correla-
tion between PIP and anti-C1q antibodies (
 
r
 
 =
 
 -
 
 0·25, 
 
P
 
 =
 
 0·02). These results
show that the PIP defect cannot be explained by low levels of C4A alone and
suggest that measurements of anti-C1q antibodies may be useful in future
studies on the molecular cause of the PIP defect in autoimmune connective
tissue disease.
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Introduction
 
The classical pathway of complement is instrumental in the
clearance of immune complexes to the liver, where they are
safely eliminated [1]. The first two components, C1 and C4
are in a crucial position in this function. Unlike C1, which
is non-polymorphic, C4 is a highly polymorphic protein,
coded for by two tandem-duplicated genes located in the
major histocompatibility complex (MHC) region on
human chromosome 6. It exists as two isotypes, C4A and
C4B, for which more than 40 allotypic variants are recog-
nized [2]. Null alleles (C4A*Q0 and C4B*Q0) producing
no identifiable product are common, and increased fre-
quency of these alleles has been observed in the immune
complex diseases (ICD), systemic lupus erythematosus
(SLE), systemic sclerosis and Henoch–Schönlein purpura
[3–8].
The high prevalence of C4A*Q0 in immune complex dis-
ease (ICD) has been linked to 
 
in vitro
 
 results indicating that
C4A binds stronger to immune complexes than C4B [9–11],
and used to argue the hypothesis that defective immune
complex clearance could play a role in the aetiology or early
pathogenesis of ICD [12–14]. This hypothesis owes its origin
to the high prevalence of ICD observed in individuals with
inherited absolute deficiencies of C1 or C4 [1,15], but to
account for the majority of cases, who do not have any obvi-
ous classical pathway abnormalities, it is assumed that even
subtotal deficiencies (e.g. resulting from partial deficiency of
C4) may play a role [12–14]. Such deficiencies are considered
to give rise to the autoimmune component of ICD through
 Immune complex handling in autoimmune disease does not depend on C4A*Q0
 
© 2005 British Society for Immunology, 
 
Clinical and Experimental Immunology
 
, 
 
140:
 
 572–579
 
573
 
chronic release of autoantigens from inflamed tissues after
immune complex deposition, and this is consistent with
results indicating that SLE autoantibodies are driven by anti-
gen [16,17]. Additional support is gained from the observa-
tion that the compounds most strongly implicated in drug-
induced lupus erythematosus (DILE) are all strong inhibi-
tors of C4A [18–21].
The main problem with the theory of complement
involvement in ICD aetiology lies in the fact that almost all
the evidence quoted so far has been circumstantial. How-
ever, we have recently confirmed that complement-depen-
dent prevention of immune precipitation (PIP) is indeed
defective in SLE patients, and that this defect is especially
prominent in the early stages of the disease [5]. The defect
was strongly correlated with low levels of C4, especially C4A,
and a similar defect which we noted on a smaller scale in
patients with systemic sclerosis was also correlated with lev-
els of C4A [7]. At first sight these results might seem to
favour the conclusion that C4A*Q0 and relative deficiency of
C4A may predispose to connective tissue disease through
defective immune complex clearance. However, one impor-
tant problem with this argumentation is that C4A*Q0 is also
a feature of several autoimmune diseases in which tissue
deposition of immune complexes has not been established
[22–34]. For further clarification of the relationship between
C4A and prevention of immune precipitation we thus
turned our attention to the C4A*Q0-associated diseases
insulin-dependent diabetes mellitus (IDDM), autoimmune
thyroid disease (Grave’s and Hashimoto’s), and the autoim-
mune gluten-sensitive diseases (GSD) [35], dermatitis her-
petiformis (DH) and coeliac disease (CD). Our results show
that prevention of immune precipitation (PIP) may be nor-
mal even in the total absence of C4A, but was below normal
in most patients who had elevated titres of IgG or IgA anti-
C1q antibodies.
 
Materials and methods
 
Patients
 
The study group consisted of 24 patients with DH, 21 with
CD, 25 with Grave’s disease, 24 with IDDM (two of whom
also had Grave’s disease) and three with Hashimoto’s disease.
The diagnosis of DH was confirmed by the presence of IgA in
the dermal papillae or in a linear granular band below the
basement membrane of uninvolved skin. Criteria for the
diagnosis of CD were (a) subjective and/or objective symp-
toms or signs of intestinal malabsorbtion; (b) total or sub-
total villous atrophy on a small intestinal biopsy; and (c)
unequivocal clinical improvement after gluten withdrawal
and/or treatment with corticoid steroids. The diagnosis of
IDDM and autoimmune thyroid disease was based on com-
mon criteria [36,37]. The DH patients were British, sampled
consecutively at St Mary’s Campus, but the remaining
patients were Icelandic, sampled consecutively at Landspitali
University Hospital. The age and male/female ratio was 21–
69 (mean 48) in DH (13 males, 11 females), 16–84 (mean 43)
in CD (seven males, 14 females), 17–56 (mean 35) in IDDM
(18 males, four females) and 24–68 (mean 40) in Grave’s
(five males, 20 females). Two females (aged 42 and 61 years)
had both IDDM and Grave’s, and two females (aged 49 and
57 years) and one male (aged 51 years) had Hashimoto’s dis-
ease. Informed consent was obtained from all patients.
 
Materials
 
Microtitre plates were purchased from Nunc (Roskilde, Den-
mark), complement fixation diluent (CFD) from Flow
(Irvine,  Scotland),  C1q,  calf  alkaline  phosphatase  (AP),
AP substrate (p-nitrophenylphosphate) and AP-conjugated
mouse 
 
a
 
-human IgG from Sigma (St Louis, MO, USA), AP-
conjugated mouse anti-IgA from BD Pharmingen (San
Diego, CA, USA), goat 
 
a
 
-human C4 from DiaSorin (Stillwa-
ter, MN, USA) and goat 
 
a
 
-calf AP from ICN/Cappel
(Aurora, OH, USA). Rabbit 
 
a
 
-human C4c, rabbit 
 
a
 
-human
C3d and AP-conjugated rabbit 
 
a
 
-mouse immunoglobulins
were from Dako (Copenhagen, Denmark) and mouse mon-
oclonal 
 
a
 
-human C4d (A213) and 
 
a
 
-human C4A (RgD1)
were from Quidell (San Diego, CA, USA) and Biotest (Dreie-
ich, Germany), respectively. In enzyme-linked immunosor-
bent assay (ELISA) measurements, phosphate buffered saline
(PBS) containing 0·05% Tween was used for diluting sera
and PBS with 0·005% Tween for washing.
 
C4 allotypes
 
All serum samples were stored at 
 
-
 
70
 
∞
 
C after collection and
kept on ice during measurements except as indicated. C4
allotypes were determined by high-voltage agarose electro-
phoresis on carboxypeptidase- and neuraminidase-treated
samples with subsequent immunofixation and staining [2].
Null alleles were determined by visual scoring of the relative
intensity of C4A and C4B bands.
 
PIP
 
PIP was measured as previously described [38]. Briefly, AP
(1/50, 5 
 
m
 
l) and goat 
 
a
 
-AP (1/5, 5 
 
m
 
l) were added to serum
(30 
 
m
 
l); after incubation (37
 
∞
 
C, 1 h) and centrifugation
(5500 
 
g
 
, 10 min), supernatants were diluted 1 : 10 in PBS
and reacted with AP substrate. Absorbance was converted to
arbitrary units (AU) by comparison to a serially diluted ref-
erence serum pool, defined as 100 AU. This assay is sensitive
to minor variations within and below the normal range
[38].
 
C3d-ELISA
 
Complement activation was assessed by monitoring serum
levels of the C3d cleavage product by an ELISA [39], using
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rabbit 
 
a
 
-C3d (1 : 1000) for coating and AP-conjugated 
 
a
 
-
C3d (1 : 2000) for developing. Sera were diluted 1 : 100 and
results expressed in AU by comparison to a serially diluted
zymosan-activated reference serum, defined as 100 AU.
Specificity for C3d was ensured by removal of larger C3 frag-
ments (C3, C3b, iC3b) by adding ethyline diamine tetra-ace-
tic acid (EDTA) (10 m
 
M
 
) to the serum and mixing it with
equal volumes of 22% polyethylene glycol, followed by incu-
bation on ice (1 h) and centrifugation (1500 
 
g
 
, 30 min) at
4
 
∞
 
C before adding it to the microtitre plate wells. Normal
levels for C3d were determined by measuring sera from 100
blood donors.
 
CH
 
50
 
, complement components and autoantibodies
 
C4 and C3 were measured by rocket immunoelectrophoresis
and total haemolytic complement (CH
 
50
 
) by standard titra-
tion methods. Results were expressed in g/l by comparison to
a known standard, or as AU by comparison to a standard
serum pool. Anti-C1q antibodies were measured by ELISA
[40], using C1q (1 : 2500) for coating and AP-conjugated
mouse 
 
a
 
-human IgG (1 : 2000) or IgA (1 : 1000) antibodies
for developing. Interference from immune complexes bind-
ing to the coated plate was avoided by increasing the molec-
ular strength (1 
 
M
 
 NaCl) of the serum dilution buffer.
Results were expressed in AU by comparison to serially
diluted reference sera with high levels of IgG or IgA 
 
a
 
-C1q
antibodies; after measuring 100 sera from blood donors, the
upper limit of normal was calculated as the average 
 
+
 
 1·96
s.d. and defined as 95 AU. The assay was calibrated against
established methods by exchange of standards, sera and
reagents between our laboratory and collaborators in Swe-
den; in our measurements, 100 AU correspond to 62 AU for
IgG and 320 AU for IgA 
 
a
 
-C1q in previous publications
[41–44].
 
C4A and C4B levels
 
Levels of C4A and total C4 were measured by a modified
ELISA [42] using goat 
 
a
 
-human C4 for coating (1 : 200) and
mouse monoclonal 
 
a
 
-human C4A (RgD1; 1/1000) or C4d
(A213; 1/2000) followed by AP-conjugated rabbit 
 
a
 
-mouse
immunoglobulin (1/1000) for developing; sera were diluted
1 : 800 and 1/1600. Results were expressed in g/l by compar-
ison to serially diluted reference serum samples from pheno-
typically homozygous C4A deficient probands or individuals
without null alleles; their C4 concentrations had previously
been determined twice by rocket immunoelectrophoresis.
C4B estimation was reached by subtracting C4A from total
C4. This approach has been validated in previous studies in
our laboratory by simultaneous measurements of C4B in
ELISA using mouse monoclonal 
 
a
 
-C4B (Mab 1228 from
Biotest).
 
Statistical analysis
 
The means of test values of patients and controls were com-
pared using the Mann–Whitney 
 
U
 
-test. PIP was compared
with other laboratory and clinical parameters using 
 
anova
 
,
 
c
 
2
 
 and Pearson’s correlation statistics. Significance was set at
 
P
 
 
 
<
 
 0·05.
 
Results
 
C4 allotypes
 
The frequency of C4A*Q0 was greatly increased in the
patients (Table 1), being 0·50 in CD (
 
P 
 
<
 
 0·001), 0·42 in DH
(
 
P 
 
=
 
 0·002), 0·30 in Grave’s disease (
 
P 
 
=
 
 0·002) and 0·23 in
IDDM (
 
P
 
 
 
=
 
 0·04) compared to 0·12 in Icelandic and 0·18 in
British controls [4,46]. The carrier frequencies were 76% in
 
Table 1.
 
Distribution of C4 allotypes in Icelandic patients with gluten-sensitive diseases (GSD), insulin-dependent diabetes mellitus (IDDM), Grave’s 
disease and Hashimoto’s disease
 
.
 
GSD IDDM Grave’s Hashimoto’s Total 
 
n
 
freq.
 
n
 
freq.
 
n
 
freq.
 
n
 
freq.
 
n
 
freq.
A*Q0 41 0·46 11 0·23 15 0·30 2 0·33 69 0·36
A*2 3 0·03 1 3 0·06 0·00 7 0·04
A*3 40 0·44 33 0·69 26 0·52 4 0·67 103 0·53
A*4 5 0·06 2 0·04 5 0·10 0·00 12 0·06
A*6 1 0·01 1 1 0·02 0·00 3 0·02
Total 90 48 50 6 194
B*Q0 1 0·01 4 0·08 1 0·02 6 0·03
B*1 84 0·93 29 0·60 37 0·74 5 0·83 155 0·80
B*2 3 0·03 9 0·19 7 0·14 1 0·17 20 0·10
B*22 1 0·02 1 0·01
B*3 2 0·02 5 0·10 4 0·08 11 0·06
B*5 1 0·02 1 0·01
Total 90 48 50 6 194
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CD (16/21 carriers, including five homozygotes), 79% in DH
(19/24 carriers, one homozygote), 54% in Grave’s disease
(14/26 carriers, one homozygote) and 42% in IDDM (10/24,
one homozygote) compared with control values of 25% in
Iceland (49/194) and 36% (24/132) in the United Kingdom
[4,46]. Two of the three patients with Hashimoto’s disease
had heterozygous C4A*Q0.
 
CH
 
50,
 
 C3d, C3, C4, C4A, C4B
 
Five patients had slightly raised C3d, indicating recent acti-
vation of complement (Fig. 1). However, measurements of
C3 and CH
 
50
 
 were normal in the patients. Levels of C4 in the
patients were suboptimal in 18 patients (Fig. 1) but were not
decreased in the whole group of patients compared to con-
trols (results not shown). The presence of C4A*Q0 was
reflected in lower levels of C4A (
 
P 
 
<
 
 0·001) as well as total C4
(
 
P 
 
=
 
 0·002) than in the remaining patients without C4A*Q0
(Fig. 2); the effect of C4B null could not be analysed mean-
ingfully as only two samples with C4B*Q0 were available for
C4 measurements.
 
PIP
 
The PIP defect shown previously in patients with SLE and
systemic sclerosis was not observed in patients with GSD,
IDDM or autoimmune thyroid disease (Fig. 3) although a
few patients were below the normal limit (
 
<
 
 68 AU). Low PIP
could neither be correlated to C4A*Q0 (Fig. 3, open and dot-
ted circles) nor complement activation as revealed by
increased C3d. On the other hand, PIP did correlate with lev-
els of C4 (
 
r
 
 
 
=
 
 0·55, 
 
P
 
 
 
=
 
 0·00000004) and surprisingly, this was
due mainly to C4B (
 
r 
 
=
 
 0·51, P = 0·0000004; Fig. 4, Table 2).
A weaker correlation was found between PIP and C3
Fig. 1. CH50 and levels of C4, C3 and C3d in 
patients with gluten-sensitive diseases (GSD), 
insulin-dependent diabetes mellitus (IDDM) 
and autoimmune thyroid disease. Horizontal 
lines denote lower normal limits for CH50, C4 
and C3, and upper normal limits for C3d.
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Fig. 2. Levels of C4 and C4A in patients with and without C4A*Q0.
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Fig. 3. Prevention of immune precipitation in patients with gluten-
sensitive diseases (GSD), autoimmune thyroid disease and insulin-
dependent diabetes mellitus (IDDM). Open circles denote heterozygous 
and dotted circles homozygous C4A*Q0 carriers. Filled circles represent 
C4A*Q0 non-carriers. Patients with Hashimoto’s disease are marked 
with arrows. Arbitary units: AU.
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(Table 2), C3 and C4B (r = 0·24, P = 0·02), and C3 and C4
(r = 0·23, P = 0·03).
Anti-C1q antibodies
Levels of anti-C1q antibodies were elevated in 20 patients,
and PIP values were markedly lower in these patients than in
patients without these antibodies (P < 0·01, Fig. 5). This was
reflected in an inverse correlation between PIP and anti-C1q
antibodies (r = - 0·25, P = 0·02) as well as an increased prev-
alence and concentration of a-C1q antibodies in patients
with PIP values close to or lower than 68 (the lower normal
limit for PIP) (Table 3). Decreased PIP values of patients
with elevated anti-C1q antibodies were not associated with
levels of C3, C4 or its isotypes, or the presence of C4 null
alleles.
Discussion
The distribution of C4 allotypes in Icelandic patients with
CD, IDDM and Grave’s disease is described here for the first
time. The frequency of C4A*Q0 turned out to be very high,
with carrier frequencies of 76%, 54% and 42% and gene fre-
quencies of 0·50, 0·30 and 0·23 in CD, Grave’s disease and
IDDM, respectively. For the British DH patients the corre-
sponding values were 79% and 0·42. An increased prevalence
of C4A*Q0 has been recorded previously in Irish [31],
American [32–33] and Italian [34] patients with autoim-
mune gluten-sensitive disease (DH or CD) and the preva-
lence is especially high in Ireland. The west of Ireland is the
geographical area with the highest rate of CD in the world
[47], possibly reflecting selective pressure from diet and his-
toric patterns of cereal digestion [48]; the recent decline in
CD among Irish children is consistent with this notion [49].
The prevalence of C4A*Q0 in DH and CD in London and
Iceland turned out to be even higher than in Ireland, and in
fact constitute the highest C4A*Q0 prevalence values so far
recorded for any disease. The prevalence of C4A*Q0 in our
patients with IDDM and Grave’s was somewhat lower but
still raised compared to controls, and this is consistent with
data from other populations [22–30].
The increased frequency of C4A*Q0 in our patient group
was reflected in low levels of the C4A protein. Other conven-
tional complement parameters, however, turned out to be
normal, allowing for optimal conditions for studying the
effect of C4A*Q0 and low C4A on prevention of immune
Table 2. Correlation between prevention of immune precipi tation 
(PIP) and other complement parameters in patients with gluten-sensi-
tive diseases (GSD), insulin-dependent diabetes mellitus (IDDM) or 
thyroid disease.
C3 C4 C4A C4B
PIP r = 0·24 r = 0·55 r = 0·25 r = 0·51
P = 0·02 P < 0·001 P = 0·02 P < 0·001
Fig. 4. Correlation of PIP to C4B*Q0 in insulin-dependent diabetes 
mellitus (IDDM), gluten-sensitive diseases (GSD) and autoimmune 
thyroid disease.
60 80 100
PIP (AU)
120 140
0·30
0·25
0·20
0·15
0·10
0·05
0·00
C4
B 
(g/
l)
r = 0·51
P = 0·00000004
Fig. 5. Prevention of immune precipitation in patients with and with-
out elevated IgG or IgA anti-C1q antibodies. AU: arbitrary units; 
 = outlier value.
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P 
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80
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High a-C1q
(n = 20)
Normal a-C1q
(n = 62)
P = 0·01
Table 3. Prevalence and levels of a–C1q antibodies in patients with gluten-sensitive diseases (GSD), insulin-dependent diabetes mellitus (IDDM) or 
thyroid disease.
High a–C1q
n
Normal a–C1q
n
P*
(Fisher exact)
Median a–C1q
(AU)
P* 
(M–W)
PIP < 68 AU 5 3 0·006 181·5 0·006
PIP 68–79 AU 6 6 0·012 76·6 0·11
PIP > 79 AU 9 53 29·0
*Compared to the group of patients with PIP >79 AU. AU: arbitary units; M-W: Mann-Whitney U test.
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precipitation. A popular theory [12–14] has suggested that
this condition leads to impaired PIP and hence to immune
complex disease. Prevention of immune precipitation, how-
ever, turned out to be entirely normal in our patient group,
and even the eight patients who had homozygous C4A*Q0
and no serum C4A had PIP values of up to 149. Measure-
ments of C4, C4A and C4B confirmed this, and showed that
PIP was correlated much more strongly with C4B than C4A.
This is in marked contrast to our previous results on patients
with SLE and scleroderma, and completely inconsistent with
the notion that defective immune complex handling in SLE
may be caused by low levels of C4A due to the presence of
C4A*Q0.
Our study contains two possible clues to the identity of
the factor(s) responsible for defective PIP. On one hand, it
seems possible that PIP may depend on levels of total C4,
and the correlation of PIP to C4B in this study and C4A in
patients with SLE and scleroderma may thus represent an
epiphenomenon. In this respect it may be pertinent that we
and others have found raised levels of C4B*Q0 in Henoch–
Schoenlein purpura [8,50,51]. Perhaps it could be postu-
lated that immune complex disease may result from subtle
defects in complement activity caused, for example, by rel-
atively low C4, and that other as yet unknown factors then
determine the exact nature of the immune complex dis-
ease.
The other explanation could relate to our finding in this
study of an inverse correlation between PIP and antibodies
to C1q (r = - 0·26, P = 0·02). Although anti-C1q antibodies
were not raised in the whole group of patients, both the prev-
alence and levels of these antibodies were raised in patients
with low PIP, and PIP was markedly lower in the 20 patients
who had raised titres of these antibodies than in the remain-
ing patients. Levels of anti-C1q antibodies are increased in
several vasculitic and nephritic disorders [52–57] and in
10% of healthy subjects, increasing with age [58]. Very high
levels of these antibodies have been considered pathogno-
monic for SLE and hypocomplementaemic urticarial vascu-
litis syndrome (HUVS); however, the distinction of the latter
disease from SLE has been questioned [59] and high titres of
these antibodies may thus prove to be the distinctive hall-
mark of SLE. Our previous findings of decreased PIP in
patients with SLE [5], together with our current findings of
an inverse relationship between PIP and anti-C1q antibod-
ies, suggest that these parameters may be correlated in SLE. It
appears quite logical to assume that cross-binding of
immune complexes by anti-C1q antibodies could interfere
with the normal handling of such complexes and instead
promote immune complex precipitation. Studies to test this
hypothesis are forthcoming.
In conclusion, complement-dependent prevention of
immune precipitation was normal in patients with GSD,
IDDM and autoimmune thyroid disease in spite of a high
prevalence of C4A*Q0 and low levels of C4A in these
patients. Defective immune complex handling may be
related to the presence of anti-C1q antibodies rather than
low levels of individual complement components.
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